Volume 6.32 | Aug 29

Immune Regulation News 6.32 August 29, 2014
Immune Regulation News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  IRN on Twitter
 
TOP STORY
Tumor-Infiltrating Gr-1+ Myeloid Cells Antagonize Senescence in Cancer
Investigators show that at the onset of senescence, PTEN null prostate tumors in mice are massively infiltrated by a population of CD11b+Gr-1+ myeloid cells that protect a fraction of proliferating tumor cells from senescence, thus sustaining tumor growth. [Nature] Abstract | Press Release
Learn more about the new smartphone app for human blood cell frequencies
 
PUBLICATIONS (Ranked by impact factor of the journal)
B Cell Homeostasis and Follicle Confines Are Governed by Fibroblastic Reticular Cells
Using a mouse model to conditionally ablate fibroblastic reticular cells (FRCs), scientists demonstrate their indispensable role in antiviral T cell responses. Unexpectedly, loss of FRCs also attenuated humoral immunity due to impaired B cell viability and follicular organization. [Nat Immunol] Abstract

Transcription Factor T-bet Regulates Intraepithelial Lymphocyte Functional Maturation
Using gene loss- and gain-of-function strategies, as well as reporter approaches, researchers show that cooperation between the transcription factors T-bet and Runx3 resulted in suppression of conventional CD4+ T helper functions and induction of an intraepithelial lymphocyte (IEL) program that included expression of IEL markers such as CD8αα homodimers. [Immunity] Abstract | Graphical Abstract | Press Release

Dendritic Cell Subsets Require Cis-Activation for Cytotoxic CD8 T-Cell Induction
Researchers show that Poly I:C (​TLR3 agonist) or ​R848 (​TLR7 agonist) do not activate all endogenous dendritic cells (DCs). ​CD11b+ DCs can orchestrate a cytotoxic T cell response in vivo in the presence of a ​TLR7 agonist but not a ​TLR3 agonist, whereas ​CD103+ DCs require ligation of ​TLR3 for this purpose. This selectivity does not extend to antigen cross-presentation for T-cell proliferation but is required for induction of cytotoxicity. [Nat Commun] Abstract

CCR2+CD103 Intestinal Dendritic Cells Develop from DC-Committed Precursors and Induce Interleukin-17 Production by T Cells
The authors show that intestinal CD103CD11b+ mononuclear phagocytes can be separated clearly into dendritic cells (DCs) and macrophages based on phenotype, gene profile, and kinetics. [Mucosal Immunol] Full Article

An In Vitro Model of Innate Lymphoid Cell Function and Differentiation
The authors describe a novel model cell line for the study of innate lymphoid cells function and differentiation. One interleukin (IL)-7-responsive subline, designated MNK-3, expresses Rorγt and produces high levels of IL-22 in response to IL-23 and IL-1β stimulation. [Mucosal Immunol] Abstract

TGF-β-Induced CD4+Foxp3+ T Cells Attenuate Acute Graft-versus-Host Disease by Suppressing Expansion and Killing of Effector CD8+ Cells
Investigators show that, as long as an appropriate generation protocol is used, TGF-β-induced CD4+Foxp3+ T cells consistently displayed a potent ability to control acute graft-versus-host disease (aGvHD) development and reduce mortality in aGvHD animal models. [J Immunol] Abstract

MicroRNA-155 Deficiency Enhances the Recruitment and Functions of Myeloid-Derived Suppressor Cells in Tumor Microenvironment and Promotes Solid Tumor Growth
Scientists demonstrate that microRNA-155 deficiency promoted solid tumor growth through increasing the recruitment of myeloid-derived suppressor cells (MDSCs) to tumor microenvironment and enhancing the tumor-promoting functions of the recruited MDSCs. [Int J Cancer] Abstract

CD4+ Foxp3+ Regulatory T Cells in Autoimmune Orchitis: Phenotypic and Functional Characterization
The phenotype and function of regulatory T cells in rats with experimental autoimmune orchitis was evaluated. CD4+CD25bright T cells from lymph nodes from the testis of experimental rats were able to suppress T cell-proliferation more efficiently than those derived from normal and control rats. [Am J Reprod Immunol]
Abstract

Anti-RAGE Antibody Ameliorates Severe Thermal Injury in Rats through Regulating Cellular Immune Function
Researchers investigated the therapeutic potential of an anti-receptor of advanced glycation end products (RAGE) neutralizing antibody for severe thermal injury in rats, and to determine whether the treatment worked via modulating cellular immune function. [Acta Pharmacol Sin] Abstract

Subscribe to our sister publications:
Human Immunology News and Immunology of Infectious Disease News
!

Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video
 
REVIEWS
The IL-23 – IL-17 Immune Axis: From Mechanisms to Therapeutic Testing
The authors focus on the recent advances that have been made regarding the transcriptional control of T helper 17 (TH17) cell plasticity and stability, as well as the effector functions of TH17 cells, and highlight the mechanisms of IL-17 signaling in mesenchymal and barrier epithelial tissues. [Nat Rev Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.
 
SCIENCE NEWS
Lilly’s Ixekizumab Superior to Etanercept and Placebo in Phase III Psoriasis Studies
Eli Lilly and Company’s investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase III studies, the company said, disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [Eli Lilly and Company] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
 
INDUSTRY NEWS
Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
Sorrento Therapeutics, Inc. announced that it has received funding to advance an immunotherapy targeting WNT1-inducible signaling protein-1 for the potential treatment of IPF. [Sorrento Therapeutics, Inc.] Press Release

Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen
Pfizer Inc. and Merck & Co. Inc. have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer. [Pfizer Inc.] Press Release

Glenmark Enters Oncology with the Discovery and the Initiation of IND Enabling Studies of an Innovative Bispecific Antibody
Glenmark Pharmaceuticals S.A. announced the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [Glenmark Pharmaceuticals S.A.] Press Release

Spring Bioscience Launches Highly Sensitive PD-L1 (SP142) Antibody for Immunotherapy Research
Spring Bioscience announced the launch of its PD-L1 rabbit monoclonal immunohistochemistry antibody. This new PD-L1 clone was developed for Roche/Genentech’s anti-PD-L1 immunotherapy development program and included in research of various tumor types. [Spring Bioscience (PR Newswire Association LLC)] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID)
October 29-November 1, 2014
Prague, Czech Republic

NEW BIT’s 8th Annual World Cancer Congress (WCC-2015)
May 15-17, 2015
Beijing, China

Visit our events page to see a complete list of events in the immune regulation community.
 
JOB OPPORTUNITIES
NEW PhD Position – Anti-Cancer γδT Cells (Free University of Brussels)

NEW Postdoctoral Position – Transplantation Aspects of Hepatocytes Derived from Human Pluripotent Stem Cells (INSERM UMR 1064 )

Research Scientist – Cellular Immunology and Oncology (Trillium Therapeutics Inc.)

Assistant Professor – Immunology (Yale University)

Postdoctoral Fellow – Innate-Adaptive Interface in Autoimmunity (Singapore Immunology Network)

Postdoctoral Research Assistant – Cardiovascular Inflammation (University of Oxford)

Postdoctoral Position – Macrophages Functions (Cochin Institute)

PhD Studentship – Regulation of Metabolism and Inflammation in Innate Immune Cells (Goethe-University Frankfurt)

PhD Studentship – Cancer Immunology (Cardiff University)

Postdoctoral Research Scientist – Virology (Cardiff University)

Postdoctoral Position – Human Heart Transplantation Immunology (Columbia University)

Principal Investigator Positions – Systems & Synthetic Biology (Institute for Research in Immunology and Cancer)

Scientist – Recombinant Molecules and Antibodies (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immune Regulation News: Archives | Events | Contact Us